M&A / Deals Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership Pharmaceutical TechnologyEli Lilly's deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.Gene Therapy PlatformRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) Pharmaceutical Technology Eli Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines. Gene Therapy Platform Read full story Post navigation Previous: Cellares and TScan to assess automated manufacturing of TSC-101 therapyNext: Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026